n.a. (APPY)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Div & Yield N.A. (N.A)

Latest News

The Value in MGT Capital Comes From Entertainment, Not Trading

The Value in MGT Capital Comes From Entertainment, Not Trading

The shares were up 11% Thursday but experts say the company's fundamentals may not support its share price.

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These under-$10 stocks are within range of triggering big breakouts.

5 Biotech Stocks Poised for Breakouts

5 Biotech Stocks Poised for Breakouts

These stocks look ready to break out and trade higher from current levels.

3 Stocks Under $10 Triggering Breakout Trades

3 Stocks Under $10 Triggering Breakout Trades

Keep these under-$10 stocks on your breakout trading radar.

APPY SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors Of Class Action Against Venaxis, Inc. And Its Board Of Directors And A Lead Plaintiff Deadline Of April 3, 2015

APPY SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors Of Class Action Against Venaxis, Inc. And Its Board Of Directors And A Lead Plaintiff Deadline Of April 3, 2015

Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Colorado on behalf of investors who purchased Venaxis, Inc.

INVESTOR ALERT: Class Action Lawsuit Against Venaxis, Inc. Announced By Law Offices Of Howard G. Smith

INVESTOR ALERT: Class Action Lawsuit Against Venaxis, Inc. Announced By Law Offices Of Howard G. Smith

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed in the United States District Court for the District of Colorado on behalf of purchasers of the securities of Venaxis, Inc.

5 Stocks Under $10 Set to Soar: Venaxis, McDermott and More

5 Stocks Under $10 Set to Soar: Venaxis, McDermott and More

These under-$10 stocks are setting up to break out and trade higher from current levels.

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Venaxis, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Venaxis, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Colorado on behalf of...

Why Venaxis (APPY) Stock Is Down Today

Why Venaxis (APPY) Stock Is Down Today

Venaxis (APPY) fell on Thursday after the diagnostic company announced the pricing of its public offering of common stock. Venaxis is offering 8,335,000 shares at $2.40 a share for a total of $20 million. The offering includes a 30-day option for underwriters to purchase up to an additional 1,250,250 shares. The offering should closed on or around April 8. Net proceeds from the offering are expected to be about $18.4 million, which Venaxis plans to use for general corporate purposes such as overhead expenses as it seeks FDA clearance for APPY1.

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These under-$10 stocks look ready to trade higher from current levels.

4 Biotech Stocks Under $10 on the Verge of Breakouts

4 Biotech Stocks Under $10 on the Verge of Breakouts

Keep these under-$10 biotech stocks on your radar.

13 Stocks Under $10 Setting up to Spike Higher

13 Stocks Under $10 Setting up to Spike Higher

These under-$10 stocks look poised to trade higher from current levels.

4 Health Care Stocks Under $10 to Watch

4 Health Care Stocks Under $10 to Watch

Keep these health care stocks under $10 on your radar.

5 Stocks Setting Up to Break Out

5 Stocks Setting Up to Break Out

These stocks look ready to break out and trade higher from current levels.

3 Stocks Under $10 Making Big Moves

3 Stocks Under $10 Making Big Moves

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

5 Biotech Stocks Under $10 Moving Higher

5 Biotech Stocks Under $10 Moving Higher

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

5 Breakout Stocks: Must-See Charts

5 Breakout Stocks: Must-See Charts

Trading stocks that trigger major breakouts can lead to massive profits.

5 Stocks Under $10 Set to Soar Higher

5 Stocks Under $10 Set to Soar Higher

Traders savvy enough to follow the low-priced names and trade them with discipline and sound risk management are banking ridiculous coin on a regular basis.

4 Biotech Stocks Under $10 Making Big Moves

4 Biotech Stocks Under $10 Making Big Moves

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

AspenBio Appoints Diagnostics Industry Veteran Don Hurd As Senior Vice President And Chief Commercial Officer

AspenBio Appoints Diagnostics Industry Veteran Don Hurd As Senior Vice President And Chief Commercial Officer

AspenBio Pharma, Inc. (Nasdaq: APPY), today announced that Don Hurd has been appointed to the new position of Senior Vice President and Chief Commercial Officer, effective May 23, 2012.

AspenBio Pharma’s Clinical Study Suggests One-Third Of CT Scans Used To Assess Pediatric And Adolescent Patients At Low Risk For Acute Appendicitis Could Potentially Be Avoided

AspenBio Pharma’s Clinical Study Suggests One-Third Of CT Scans Used To Assess Pediatric And Adolescent Patients At Low Risk For Acute Appendicitis Could Potentially Be Avoided

Results from AspenBio Pharma’s (NASDAQ: APPY) recently completed 503-patient pilot study of AppyScore™ will be presented from the podium at the upcoming annual scientific meeting of the Society for...

Results Of 503-Patient Clinical Study Of AspenBio Pharma’s AppyScore™ Blood Test Show 97% Negative Predictive Value For Absence Of Acute Appendicitis In Children And Adolescents Presenting With Abdominal Pain

Results Of 503-Patient Clinical Study Of AspenBio Pharma’s AppyScore™ Blood Test Show 97% Negative Predictive Value For Absence Of Acute Appendicitis In Children And Adolescents Presenting With Abdominal Pain

The results from AspenBio Pharma’s (NASDAQ: APPY) 503-patient pilot study of AppyScore™ will be presented from the podium the upcoming West Region meeting of the Society for Academic Emergency Medicine...

Study Demonstrates AspenBio Pharma’s AppyScore Multi-Marker Blood Test Highly Predictive For Absence Of Acute Appendicitis In Children With Abdominal Pain

Study Demonstrates AspenBio Pharma’s AppyScore Multi-Marker Blood Test Highly Predictive For Absence Of Acute Appendicitis In Children With Abdominal Pain

The final results from AspenBio Pharma’s (NASDAQ: APPY) 503-patient pilot study of AppyScore™ will be presented from the podium at the annual meeting of the Society for Academic Emergency Medicine being...

Biotech Sector Weekly Rewind

Adam Feuerstein's take on the biotech sector's hits and misses during the week ended Nov. 12, 2010.

The Law Office Of Robbins Umeda LLP Announces The Filing Of A Class Action Suit Against AspenBio Pharma, Inc.

Robbins Umeda LLP today announced that a class action has been commenced in the U.

Investor Notice: The Rosen Law Firm Announces Investigation Of Shareholder Securities Claims Against AspenBio Pharma, Inc. --- APPY

The Rosen Law Firm today announced that it has commenced an investigation into allegations that AspenBio Pharma, Inc.